Free Trial
NASDAQ:PETV

PetVivo Q4 2024 Earnings Results & Report

PetVivo logo
$0.56 -0.02 (-3.79%)
As of 03:12 PM Eastern

PetVivo reported Q4 2024 earnings on June 28, 2024. The company reported EPS of -$0.14, while revenue was $50 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date

PetVivo EPS Results

Actual EPS
-$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PetVivo Revenue Results

Actual Revenue
$50 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

PetVivo's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

PetVivo Q4 2024 Earnings FAQ

PetVivo (NASDAQ:PETV) reported earnings of -$0.14 per share for Q4 2024. The report was announced on Friday, June 28, 2024.

PetVivo reported revenue of $50 thousand for Q4 2024.

PetVivo's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for PetVivo on the company's earnings history page.

PetVivo Earnings Headlines

Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors
Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
See More PetVivo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetVivo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetVivo and other key companies, straight to your email.

About PetVivo

PetVivo (NASDAQ:PETV) is a biomedical company focused on developing and commercializing medical therapeutics and devices for use in animals and, potentially, humans. The company’s technologies are designed to address conditions involving damaged or diseased tissue, with an emphasis on minimally invasive treatments.

PetVivo’s principal commercial product is Spryng with OsteoCushion Technology, an injectable product administered by veterinary professionals. It is intended to help manage lameness associated with osteoarthritis and other joint-related conditions in animals, including dogs and horses. The company continues to develop additional products based on its proprietary platform for regenerative and tissue-support applications.

Based in Minneapolis, Minnesota, PetVivo primarily serves the veterinary healthcare market through animal-health professionals and related distribution channels. John Lai serves as the company’s chief executive officer. The company has also indicated that its technologies may have future applications in human healthcare, subject to further development and regulatory approval.

View PetVivo Profile